OABIW
IndustrialsOmniAb Inc.
Live · NASDAQ · May 13, Close
What's Moving OABIW Today?
No stock-specific AI insight has been generated for OABIW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.12
Fundamentals
Trading
OABIW News
20 articles- OmniAb (OABI) Q1 2026 Earnings TranscriptMotley Fool·May 8, 2026
- OmniAb, Inc. Q1 2026 Earnings Call SummaryMoby·May 8, 2026
- OmniAb Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 8, 2026
- OmniAb Reports First Quarter 2026 Financial Results and Business HighlightsYahoo Finance·May 7, 2026
- OmniAb to Participate in Three Upcoming Investor ConferencesYahoo Finance·Apr 24, 2026
- Bullish OmniAb Insiders Loaded Up On US$1.28m Of StockYahoo Finance·Apr 22, 2026
- OmniAb to Report First Quarter 2026 Financial Results on May 7Yahoo Finance·Apr 21, 2026
- OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026Yahoo Finance·Apr 14, 2026
- Here Is Why You Should Not Ignore OmniAb Inc. (OABI)Yahoo Finance·Mar 31, 2026
- OmniAb to Participate at the Leerink Partners Global Healthcare ConferenceYahoo Finance·Feb 24, 2026
- OmniAb to Report Fourth Quarter 2025 Financial Results on March 4Yahoo Finance·Feb 19, 2026
- John Higgins Bought 3.5% More Shares In OmniAbYahoo Finance·Nov 13, 2025
- Analysts Have Been Trimming Their OmniAb, Inc. (NASDAQ:OABI) Price Target After Its Latest ReportYahoo Finance·Nov 8, 2025
- OmniAb (OABI): Rapid 30.4% Revenue Growth Forecast Raises Questions for Loss-Weary InvestorsYahoo Finance·Nov 6, 2025
- OmniAb Inc (OABI) Q3 2025 Earnings Call Highlights: Strong Program Momentum Amid Revenue DeclineYahoo Finance·Nov 5, 2025
- OmniAb, Inc. (OABI) Reports Q3 Loss, Misses Revenue EstimatesYahoo Finance·Nov 4, 2025
- OmniAb Reports Third Quarter 2025 Financial Results and Business HighlightsYahoo Finance·Nov 4, 2025
- OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy?Yahoo Finance·Oct 28, 2025
- Insider Stock Buying Reaches US$1.48m On OmniAbYahoo Finance·Oct 28, 2025
All 20 articles loaded
Price Data
52-Week Range
$0.12
Fundamentals
Trading
About OmniAb Inc.
OmniAb Inc. is a prominent biotechnology firm specializing in the discovery and development of fully human therapeutic antibodies via its proprietary OmniAb platform. This advanced platform enables the generation of highly diverse antibody libraries, placing OmniAb at the vanguard of drug development, especially within oncology and autoimmune disorders. With a strong pipeline and strategic collaborations, the company is well-positioned to leverage the growing demand for innovative antibody therapies, aligning with major trends in biotechnology and personalized medicine to improve patient outcomes and foster sustainable growth.